Overall survival. In the treatment-naive study (A), 3-year survival was 63%. In the relapsed study (B), 3-year survival was 86%. In the refractory study (C), 3-year survival in the alemtuzumab arm (blue) was approximately 20% higher than rabbit ATG (red), but this difference was not statistically significant. The dotted lines in the treatment-naïve and relapse study panels represent 95% CI. The median survival was not reached in any of the treatment arms in any of the studies.